Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of "Moderate Buy" from Brokerages
Biohaven Ltd. (NYSE:BHVN) has received a "Moderate Buy" consensus rating from seventeen research firms, with an average 12-month price target of $21.75. The company's shares opened at $13.59, and it recently reported a quarterly EPS of negative $0.91, missing the consensus estimate. Institutional investors hold 88.78% of the stock, and analysts anticipate a full-year loss of approximately $3.11 per share.
Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP
Quantinno Capital Management LP significantly increased its stake in Biohaven Ltd. (BHVN) by 190% in the first quarter, bringing its total to 121,554 shares. Several other institutional investors also expanded their positions, contributing to the high institutional ownership of 88.78%. Despite a reported quarterly loss of $0.91 per share, analysts maintain a "Moderate Buy" rating with a consensus price target of $21.75, considerably higher than the stock's recent trading price.
Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)?
Biohaven Ltd. reported narrowing losses in Q2 2026, with a net loss of US$137.31 million. The company also appointed AI-focused investor John Yetimoglu to its Board, signaling a push to integrate advanced computation into R&D. Despite these developments, the article emphasizes that Biohaven's investment narrative still heavily relies on the success of its epilepsy and MoDE degrader programs, given its zero revenue and short cash runway.
Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands
Biohaven (BHVN) is gaining attention due to an expanded oncology collaboration with Regeneron Pharmaceuticals, though its long-term shareholder returns have been weak. A Simply Wall St discounted cash flow (DCF) model estimates a fair value of $54.53, suggesting the stock is significantly undervalued compared to its current price of $14.64, despite ongoing losses and high valuation risks based on its P/B ratio. Investors are advised to examine underlying data and warnings signs before making decisions.
Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands
Biohaven (BHVN) has expanded its oncology collaboration with Regeneron Pharmaceuticals, leading to recent stock momentum despite a longer history of weak returns and losses. Simply Wall St's Discounted Cash Flow (DCF) model estimates BHVN to be 73% undervalued with a fair value of $54.53 against its current trading price of $14.64, based on assumptions of future revenue and cash generation. However, the company faces significant clinical and regulatory hurdles, and its high Price-to-Book ratio of 180.9x compared to an industry average of 2.5x suggests high valuation risk.
Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands
Biohaven (BHVN) is gaining attention after expanding its oncology collaboration with Regeneron Pharmaceuticals. Despite a recent slight easing in share price, the stock shows strong 90-day returns, contrasting with weaker long-term performance. A discounted cash flow (DCF) model by Simply Wall St suggests Biohaven could be 73% undervalued, estimating a fair value of $54.53 against its current trading price of $14.64, although its high P/B ratio indicates significant valuation risk.
Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)?
Biohaven Ltd. reported narrowing losses in Q2 2026, with a net loss of US$137.31 million, and appointed AI-focused investor John Yetimoglu to its Board. Despite these developments, the company still faces significant financial risk due to zero revenue, heavy ongoing losses, and a short cash runway, with investors needing to consider future funding and potential dilution. The article suggests that while the AI appointment aligns with Biohaven's data-driven R&D, it doesn't immediately alter the key value drivers of its epilepsy and MoDE degrader programs.
Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven
Woodline Partners LP has reported a beneficial ownership of 5.1% in Biohaven Ltd., amounting to 7,660,280 Common Shares. This ownership grants Woodline Partners sole voting and dispositive power over these shares, which are held through Woodline Master Fund LP and Woodline Spire Master Fund LP. The stake is based on Biohaven's 150,560,990 Common Shares outstanding as of April 30, 2026.
Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN
Renaissance Technologies LLC has acquired a new position in Biohaven Ltd. (NYSE:BHVN), purchasing 160,952 shares valued at approximately $1.36 million. This move comes as institutional investors collectively own 88.78% of Biohaven, with several major funds significantly increasing their stakes. Despite missing quarterly EPS expectations, analysts maintain a "Moderate Buy" rating with an average price target of $21.75 for Biohaven.
Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)?
Biohaven Ltd. reported narrower losses in Q2 2026 and appointed an AI-focused investor to its board, signaling a push into advanced computation for R&D. Despite this, the company still faces significant financing risk due to ongoing heavy losses and a short cash runway, with pivotal trial readouts remaining key value drivers. Investors must consider future funding and potential dilution alongside the company's volatile stock price and differing fair value estimates.
Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)
Bank of America Securities has reiterated a Buy rating on Biohaven Ltd. (BHVN) with a price target of $11.00, despite the stock closing higher at $14.54. Analyst Dina Ramadane, who covers the Healthcare sector, has a 61.54% success rate on her recommendations. The broader analyst consensus for Biohaven Ltd. is a Moderate Buy with an average price target of $16.33.
Biohaven Pharma stock price target raised to $23 by RBC Capital
RBC Capital has raised its price target for Biohaven Pharma (NYSE:BHVN) to $23 from $22, maintaining an Outperform rating, following the company's second-quarter 2026 earnings report. The firm highlights potential opportunities in troriluzole and degrader data, estimating a more than $4 billion market by 2035, and anticipates success in the near-term Kv7 readout. Despite some elevated spending and concerns about cash burn, the pipeline is deemed attractive, and the company is progressing with other trials like RISE3 for epilepsy and a Phase 3 trial for Graves’ disease.
Biohaven (NYSE: BHVN) reports $267.8M H1 2026 loss and $267.9M in liquidity
Biohaven Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company, reported a net loss of $267.8 million for the first half of 2026, primarily due to $204.6 million in research and development expenses. The company maintains liquidity with $267.9 million in cash, cash equivalents, and marketable securities, which management expects to fund operations for at least one year. Biohaven is focused on advancing its R&D portfolio across immunology, obesity, neuroscience, and oncology, including key clinical programs such as Kv7 ion channel modulation for epilepsy and Molecular Degrader of Extracellular Proteins (MoDE) for immunological diseases.
Biohaven (NYSE:BHVN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
Biohaven (NYSE:BHVN) announced its quarterly earnings, reporting a loss of $0.78 per share, which missed analysts' consensus estimates by $0.02. Following the announcement, shares of Biohaven dropped 0.5% to $14.58. Despite the earnings miss, analyst sentiment for Biohaven remains a "Moderate Buy" with an average price target of $21.62.
Biohaven Ltd. $BHVN Shares Purchased by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company increased its stake in Biohaven Ltd. (NYSE:BHVN) by 52.5% in Q1, now owning 202,975 shares valued at $1.72 million. Other institutional investors also significantly increased their holdings, with hedge funds and institutional investors collectively owning 88.78% of the stock. Analysts currently rate Biohaven as a "Moderate Buy" with an average price target of $21.62.
Biohaven Ltd. Announces Q2 2026 Financial Results Highlighting Reduced Losses and R&D Spending
Biohaven Ltd. has filed its Q2 2026 financial report, revealing continued operating losses but also a reduction in research and development spending compared to the previous year. This report covers the three- and six-month periods ending June 30, 2026. The full details are available via an SEC Form 10-Q filing.
Biohaven earnings set to show cash burn ahead of epilepsy data
Biohaven Pharmaceutical Holding Co Ltd is expected to report its second-quarter earnings, with analysts forecasting a narrower loss of 75 cents per share. Investors will be closely watching the company's cash burn rate and updates on its epilepsy drug candidate, opakalim, which has topline results expected in the second half of 2026. The stock faces skepticism from some analysts due to competitive concerns and cash runway, while others maintain a positive outlook.
Understanding Momentum Shifts in (BHVN)
This article analyzes Biohaven Ltd. (BHVN) stock, highlighting a potential shift where strong near-term sentiment might challenge persistent mid and long-term weakness. It identifies resistance testing and outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones for different risk profiles. The analysis emphasizes risk-reward scenarios and multi-timeframe signal insights.
Biohaven Ltd. Announces Appointment of John Yetimoglu to Board of Directors, Effective August 6, 2026
Biohaven Ltd. has announced the appointment of John Yetimoglu to its Board of Directors and as a member of the Nominating and Governance Committee, effective August 6, 2026. Mr. Yetimoglu, founder and CIO of Infinitum, brings expertise in semiconductors, videogaming, and AI application platforms. His appointment is expected to enhance the company's strategic oversight in leveraging AI and advanced computational methods for medical breakthroughs.
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
Biohaven Ltd. (NYSE: BHVN) has appointed John Yetimoglu, founder and CIO of Infinitum and a board director at Groq, to its Board of Directors. Yetimoglu brings extensive experience in frontier AI and technology investing, which Biohaven anticipates will strengthen its strategic oversight as it integrates AI, machine learning, and advanced computational methods into drug discovery and development. This appointment highlights Biohaven's belief in the convergence of biology, data, and computation to drive future medical breakthroughs.
Biohaven Ltd. (BHVN) Stock Price, News, Quote & History
This Yahoo Finance page provides detailed stock information for Biohaven Ltd. (BHVN), including its current stock price, historical data, key events, and financial metrics. The company, a biopharmaceutical firm, focuses on treatments for immunology, neuroscience, and oncology, with several drug candidates in various clinical trial phases. The page also offers analyst insights, performance comparisons against the S&P 500, and a list of similar biotechnology companies.
Biohaven (BHVN) Adds AI Expertise To Its Board, Is The Valuation Gap Too Wide?
Biohaven (BHVN) recently appointed John Yetimoglu, an AI-focused investment leader, to its Board, signaling a stronger push into data-driven drug discovery. Despite recent stock volatility, a Discounted Cash Flow (DCF) model suggests Biohaven is significantly undervalued at $13.63, with a fair value estimate of $58.37 per share, driven by high future growth assumptions. However, its high Price-to-Book (P/B) ratio of 15.8x compared to industry averages and risks like limited cash runway and potential shareholder dilution present a mixed valuation picture.
Biohaven Adds Technology Investor John Yetimoglu to Board as AI Strategy Advances
Biohaven Ltd. (NYSE: BHVN) has appointed technology investor John Yetimoglu to its Board of Directors to bolster its artificial intelligence and computational technologies strategy in drug discovery and development. Yetimoglu, founder of Infinitum and an early investor in Groq, brings extensive experience in emerging technologies and AI infrastructure to the biopharmaceutical company. This appointment reflects a growing trend in the life sciences industry to integrate AI expertise at the board level to accelerate innovation and decision-making.
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
Biohaven Ltd. has appointed technology investor John Yetimoglu to its Board of Directors. Yetimoglu, founder of Infinitum and a board director at Groq, brings expertise in frontier AI and technology investing. His appointment aims to strengthen Biohaven's strategic oversight as the company integrates AI and computational methods into its drug discovery and development processes.
Biohaven Pharma earnings on deck amid epilepsy trial scrutiny
Biohaven Pharmaceutical Holding Co. is set to report second-quarter results, with analysts anticipating a narrower loss per share. Investors will be closely watching for updates on the company's cash runway and the timeline for pivotal Phase 2/3 epilepsy trial results for its experimental drug, opakalim, especially given growing skepticism about its differentiation from rivals. The company's recent restructuring efforts and upcoming clinical data are crucial for its valuation.
Biohaven Insiders Added US$33.1m Of Stock To Their Holdings
This article discusses recent insider purchases at Biohaven Pharmaceutical Holding Company. Insiders bought US$33.1 million worth of stock, suggesting confidence in the company's future despite a recent share price decline. The purchases come after the company's acquisition of a migraine drug by Pfizer, which resulted in a significant special dividend for shareholders.
Biohaven Ltd (BHVN) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for Biohaven Ltd (BHVN), covering operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and Biohaven's specific cash flow figures for operating, investing, financing, and free cash flow in recent periods. The data aims to help users evaluate the company's financial soundness and stability.
Biohaven (BHVN) Following Its Court Win Still Looks Cheap Against Fair Value
Biohaven (BHVN) recently won a federal jury case related to misappropriated trade secrets, yet its share price has seen a short-term decline despite strong 90-day and year-to-date gains. A Discounted Cash Flow (DCF) model estimates Biohaven's fair value at $61.24, significantly higher than its current trading price of $13.77, suggesting it is undervalued. However, the company faces risks due to a lack of current revenue and potential clinical trial setbacks, and its high Price-to-Book ratio of 16x raises questions about how much future success is already factored into its valuation.
Yale, Biohaven Win $4M In Biotech Trade Secret Trial
A Delaware federal jury has awarded Yale University and Biohaven Therapeutics $4 million in a trade secret trial. The verdict found venture capital firm RA Capital Management GP breached a confidentiality agreement and, along with Avilar Therapeutics, misappropriated a Yale-developed trade secret for designing protein-degrading drug molecules.
Biohaven and Yale win $4M verdict in trade secret case
A federal jury awarded Biohaven Ltd. and Yale University $4 million in a trade secret misappropriation case against Avilar Therapeutics, Inc. and RA Capital Management GP, LLC. The jury found that Avilar and RA Capital willfully and maliciously misappropriated a Yale trade secret related to its MODA targeted protein degradation platform and that RA Capital breached its 2019 confidentiality agreement with Yale. The damages include $2 million to Yale for breach of contract and $1 million each to Yale and Biohaven for trade secret misappropriation.
Yale, Biohaven Win $4M In Biotech Trade Secret Trial
A Delaware federal jury has awarded Yale University and Biohaven Therapeutics $4 million in a biotech trade secret trial. The verdict found that venture capital firm RA Capital Management GP breached a confidentiality agreement and, along with Avilar Therapeutics, misappropriated a Yale-developed trade secret for designing protein-degrading drug molecules.
Yale, Biohaven Win $4 Million Verdict Over Drug-Development Tech
Yale University and Biohaven Therapeutics Ltd. were jointly awarded $4 million in a Delaware trial. The verdict found Avilar Therapeutics Inc. and RA Capital Management GP LLC liable for misappropriating Yale's "MODA" drug-development trade secret and for breaching a confidentiality agreement. The jury specifically awarded Yale $2 million, with the total verdict reaching $4 million.
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million
A federal jury found Avilar Therapeutics and RA Capital Management GP, LLC guilty of willfully and maliciously misappropriating a trade secret developed at Yale University related to its "MODA" targeted protein degradation platform. RA Capital was also found to have breached a confidentiality agreement with Yale. The jury awarded Biohaven Ltd. and Yale University a combined $4 million in damages for trade secret misappropriation and breach of contract.
How Biohaven’s (BHVN) Trade Secret Verdict Shapes Its Intellectual Property Defense Strategy
Biohaven recently won a US$1,000,000 trade secret lawsuit, reinforcing its commitment to protecting intellectual property. While this win strengthens the narrative around IP quality, it doesn't change the company's core investment risks, which include clinical outcomes, funding needs, and potential shareholder dilution. Biohaven remains a high-risk, pre-revenue biotech focused on its clinical pipeline.
Biohaven Ltd (BHVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Biohaven Ltd (BHVN) stock, focusing on various indicators and moving averages. It presents a summary of buy, neutral, and sell signals derived from tools such as MACD, RSI, and different moving average periods. The analysis concludes with a neutral signal based on today's moving averages and other technical indicators.
BHVN|Biohaven Ltd|Price:14.320|Chg%:-0.320
This article provides a detailed financial overview of Biohaven Ltd (BHVN), including key financial indicators, income statements, balance sheets, and cash flow statements for various quarters and fiscal years. It highlights the company's latest earnings, revenue forecasts, and analyst ratings, presenting a comprehensive data dashboard for investors to analyze its market health. The report also includes FAQs addressing specific financial metrics from Biohaven Ltd's FY2025 earnings report.
Biohaven Pharmaceutical Holding Company Ltd (BHVN) Earnings, Actual EPS, EPS Estimates & Results
This article provides detailed earnings information for Biohaven Pharmaceutical Holding Company Ltd (BHVN), including actual EPS, EPS estimates, and results. It highlights upcoming Q2 '26 earnings with an estimated EPS of -$0.75 and an estimated revenue of $0M. The company's historical quarterly performance shows a mix of missed and beat EPS estimates.
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
Biohaven Ltd. will present new Phase 1 clinical data on its FGFR3-directed antibody-drug conjugate (ADC) BHV-1530 at the ESMO Congress 2026. The data shows early tumor reductions in various advanced solid tumors with a differentiated safety profile, and Biohaven has also partnered with Regeneron to evaluate BHV-1530 in combination with cemiplimab. BHV-1530 aims to target FGFR3 regardless of alteration status, potentially expanding the addressable patient population beyond current FGFR tyrosine kinase inhibitors.
How Biohaven’s (BHVN) R&D Leadership Shuffle Will Impact Investors
Biohaven Ltd. recently reshuffled its R&D leadership, with Chief Scientific Officer Bruce Car transitioning to a part-time Chief Innovation Officer role and David Pirman promoted to head of discovery. This reorganization aims to separate external innovation from internal discovery, which could clarify accountability but also centralizes scientific leadership in new management. While the changes don't immediately impact near-term clinical catalysts, investors should monitor the execution risk given Biohaven's zero revenue, short cash runway, and ongoing losses.
Biohaven files Form 3 for Chief Legal Officer Warren Karl Volles
Biohaven's Chief Legal Officer, Warren Karl Volles, has filed a Form 3, disclosing ownership of 248,212 common shares and stock options for 731,000 shares. This disclosure was made public via the U.S. SEC's EDGAR system on July 17, 2026. The information was initially created by Public Technologies (PUBT) using generative AI for informational purposes.
Biohaven Ltd. (NYSE: BHVN) legal chief discloses holdings
Biohaven Ltd.'s Chief Legal Officer, Warren Karl Volles, has filed an initial statement of beneficial ownership, disclosing holdings including 248,212 Common Shares acquired directly and through an employee plan, 14,000 restricted share units, and various stock options totaling over 700,000 underlying common shares. These holdings and their vesting schedules were detailed in a recent SEC Form 3 filing. The filing outlines the exercise prices and expiration dates of the numerous stock options, with some portions already exercisable and others vesting through 2029, 2032, 2033, 2034, 2035, and 2036.
Lobbying Update: $120,000 of BIOHAVEN LTD. lobbying was just disclosed
BIOHAVEN LTD. (BHVN) recently disclosed $120,000 in lobbying expenditures for Q2 2026, primarily focused on advocacy for patients with rare diseases. The article also details recent hedge fund activity, showing significant adds and removals of BHVN shares, and lists price targets from six analysts with a median target of $17.5.
Lobbying Update: $120,000 of BIOHAVEN LTD. lobbying was just disclosed
BIOHAVEN LTD. (BHVN) recently disclosed $120,000 in lobbying expenditures for Q2 2026, focusing on advocacy for patients with rare diseases. The article also details hedge fund activity in BHVN stock, with several large institutional investors adding or removing shares, and lists recent analyst price targets for the company.
Price to book forward of Biohaven Ltd. – NYSE:BHVN
The article provides a brief financial snippet for Biohaven Ltd. (NYSE: BHVN), specifically focusing on its "Price to book forward" metric. It appears to be a data point derived from a financial platform, showing the value and change for this specific period. The content is sparse, primarily acting as a label for a financial data point.
Discipline and Rules-Based Execution in BHVN Response
This article provides an analysis of Biohaven Ltd. (BHVN) leveraging AI models to generate trading strategies across different risk profiles. It highlights near-term weak sentiment, identifies potential long-term weakness, and offers specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies. The analysis is based on multi-timeframe signal analysis and institutional trading strategies.
Price to earnings forward of Biohaven Ltd. – BOATS:BHVN
This page provides financial information for Biohaven Ltd. (BHVN), specifically focusing on its forward price-to-earnings ratio. It is hosted on TradingView, a platform offering market data, financial tools, and community features for traders and investors.
Biohaven Research Ltd Shs Unsponsored Brazilian Depositary Receipt Repr 0.33333333 Shs
The article focuses on the "Price to book forward" for Biohaven Research Ltd Shs Unsponsored Brazilian Depositary Receipt Repr 0.33333333 Shs (BHVN34) traded on B3. It displays the stock's ticker, current market status, and various financial and technical data sections available on TradingView. The main content is about financial metrics for this specific stock.
Biohaven reshuffles scientific leadership as Car steps back
Biohaven (NYSE: BHVN) announced significant scientific leadership changes effective July 13, 2026. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, overseeing internal drug discovery. Bruce Car, Ph.D., is transitioning from his role as Chief Scientific Officer to a part-time Chief Innovation Officer, focusing on external collaborations including the Bexorg partnership, while Warren Volles, General Counsel, is now also an executive officer.
Enterprise value to EBIT forward of Biohaven Ltd. – BOATS:BHVN
This article provides financial information for Biohaven Ltd. (BHVN), specifically its enterprise value to EBIT forward. It indicates various sections typically found on financial platforms, such as an overview, financials, news, and community features, but the core content only presents the enterprise value to EBIT forward data without further analysis.
Biohaven (BHVN) Advances Key Trials Following Pipeline Progress While Valuation Still Looks Pricey
Biohaven (BHVN) has reached two significant clinical milestones, completing enrollment for its RISE3 opakalim epilepsy trial and initiating Phase 3 testing for BHV-1300 in Graves' disease, leading to a recent surge in its stock price. Despite this positive momentum and a 51.4% 30-day share price return, the company's valuation appears high with a P/B ratio of 19.5x, significantly above industry averages, suggesting a premium based on future potential rather than current financials. The article advises caution due to the company's loss-making status and the high valuation, emphasizing the risks associated with potential clinical trial setbacks.
